Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GRAIL, Inc. - Common Stock
(NQ:
GRAL
)
99.25
-5.59 (-5.33%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GRAIL, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
What's Behind Grail Stock's Wild Ride in 2026, and What Can Investors Expect in 2027?
↗
Today 1:27 EST
The multi-cancer early detection test company's volatility is likely to continue next year.
Via
The Motley Fool
Topics
Artificial Intelligence
Death
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
November 20, 2026
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates
From
FN Media
Via
GlobeNewswire
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
November 20, 2026
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:GH),(NASDAQ:GRAL),(NASDAQ:NTRA),(NASDAQ:FRNM) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
GRAIL (NASDAQ:GRAL) Slides After Q3 Revenue Miss Despite Narrower Loss
↗
November 04, 2026
Via
Chartmill
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?
↗
November 19, 2026
Grail's cancer blood test faces a setback in a major UK trial, while Tempus AI's data business is growing fast but still losing money. The two carry very different risk profiles.
Via
The Motley Fool
Topics
Artificial Intelligence
GRAIL: 3 Key Takeaways for Long-Term Investors
↗
November 19, 2026
Promotional pricing trades near-term margin for adoption, and that bet only pays off if per-test costs fall as volumes scale.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
Got $10,000? 3 Hot Stocks to Buy That Could Make You a Fortune
↗
November 10, 2026
Grail, Agility Robotics, and Sandisk could deliver multibagger gains in the future.
Via
The Motley Fool
GRAIL (GRAL) Q3 2026 Earnings Call Transcript
↗
November 05, 2026
Promotional pricing lifted test volume sharply, but margins fell and losses widened.
Via
The Motley Fool
Topics
Earnings
What GRAIL (GRAL) Said on Its Q3 Earnings Call
↗
November 04, 2026
GRAIL (NASDAQ:GRAL) reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri...
Via
MarketBeat
Topics
Earnings
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
↗
October 26, 2026
Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.
Via
MarketBeat
Topics
Artificial Intelligence
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
↗
October 11, 2026
FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
Via
The Motley Fool
2 Growth Stocks to Buy in October
↗
October 08, 2026
Grail and Veeva Systems could be well insulated from near-term headwinds.
Via
The Motley Fool
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
↗
October 04, 2026
Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections.
Via
The Motley Fool
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
↗
September 30, 2026
The cancer blood test maker could have a bright future.
Via
The Motley Fool
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
↗
September 30, 2026
A positive FDA vote is driving the recent surge in the multi-cancer early detection (MCED) test company.
Via
The Motley Fool
Here's Why Grail Stock Surged 55% This Week
↗
September 25, 2026
The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.
Via
The Motley Fool
Topics
Death
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade
↗
September 22, 2026
Via
Chartmill
Topics
Artificial Intelligence
Let's take a look at the stocks that are in motion in today's session.
↗
September 21, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Monday?
↗
September 21, 2026
Via
Chartmill
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000
↗
September 08, 2026
An insider sells 7,900 shares as the stock price has surged over the past year.
Via
The Motley Fool
Topics
Regulatory Compliance
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
↗
September 04, 2026
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock.
Via
The Motley Fool
Topics
Earnings
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
↗
August 14, 2026
GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital...
Via
MarketBeat
GRAIL (GRAL) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Galleri volume jumped 35% year over year on physician adoption and digital partnerships.
Via
The Motley Fool
Topics
Earnings
GRAIL Q2 Earnings Call Highlights
↗
August 05, 2026
GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build...
Via
MarketBeat
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
August 04, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
August 03, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?
↗
August 01, 2026
The developer of blood-based cancer tests still has a bright future.
Via
The Motley Fool
GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights
July 30, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol
July 29, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.